title: Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure.
abstract: Short-term infusion of carperitide (atrial natriuretic peptide) has beneficial effects on neurohumoral factors; however, it remains unclear whether the effects are sustained for long-term infusion. To evaluate the effects of long-term infusion of carperitide on neurohumoral factors in patients with chronic congestive heart failure (CHF), we measured neurohumoral factors before and 1 hour after stopping carperitide infusion in 42 CHF patients. Carperitide infusion was continued for more than 2 days until there was symptomatic improvement of CHF. Patients were divided into 2 groups by the median value of infusion duration: group 1 (less than 7 days, n=21) and group 2 (more than 7 days, n=21). In group 1, aldosterone (ALD) and endothelin-1 (ET-1) were significantly increased after stopping carperitide. In contrast, ALD and ET-1 did not change after stopping carperitide in group 2. The molar ratio of cyclic guanosine monophosphate/atrial natriuretic peptide before stopping carperitide was significantly lower in group 2 than in group 1. Suppression of ALD and ET-1 was maintained for 7 days of carperitide infusion, but the beneficial effect on neurohumoral factors was attenuated after more than 7 days, probably through down-regulation of biologic receptors coupled with guanylate cyclase in CHF patients.
authors.affiliation: Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu 520-2192, Japan.
authors.forename: Chitose
authors.initials: C
authors.lastname: Ishikawa
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Tsutamoto
authors.forename: Atsuyuki
authors.initials: A
authors.lastname: Wada
authors.forename: Masanori
authors.initials: M
authors.lastname: Fujii
authors.forename: Keijin
authors.initials: K
authors.lastname: Ohno
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sakai
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Minoru
authors.initials: M
authors.lastname: Horie
mesh_terms: D000450:Aldosterone / Q000378:metabolism*; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002311:Cardiomyopathy, Dilated / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D002908:Chronic Disease; D006152:Cyclic GMP / Q000097:blood; D019332:Endothelin-1 / Q000378:metabolism*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D020097:Natriuretic Peptide, Brain / Q000097:blood; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019332:Endothelin-1; C472955:NPPA protein, human; D020097:Natriuretic Peptide, Brain; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D006152:Cyclic GMP